Real-World Adherence and Effectiveness of Inclisiran in Lowering LDL-C: Results from 1 Year of Follow-Up
Inclisiran significantly reduced LDL-C. The dosing schedule promoted high adherence in a real-world setting, particularly among older adults with ASCVD. These findings indicate inclisiran may be a particularly valuable addition to lipid-lowering strategies.
Authors
- Bruce Iteld
- Lucinda J. Van Anglen (ORCID: https://orcid.org/0000-0001-9135-096X)
- Sean McElligott (ORCID: https://orcid.org/0000-0001-9453-1432)
- Harvey Serota
- Christie Mitchell Ballantyne (ORCID: https://orcid.org/0000-0002-6432-1730)
- Tyler J. Varisco (ORCID: https://orcid.org/0000-0001-9795-8837)
- Timothy E. Graham
- Xiaoli Niu
- Kelly E. Hanna
Institutions
- Baylor College of Medicine (US)
- Heart Clinic of Louisiana (US)
- Novartis (United States) (US)
- Diabetes & Endocrinology Specialists (US)
- Houston Methodist Sugar Land Hospital (US)
- Healing Foundation (AU)
- University of Houston (US)
- Saint Louis University (US)
Publication Details
- Journal
- Cardiology and Therapy
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1007/s40119-025-00438-0
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novartis Pharmaceuticals Corporation